Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets

NCT07850765 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07850765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
August 28, 2026
Completion date
August 31, 2026
Enrollment
1,260 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight